Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Assets Average (2019 - 2025)

Historic Assets Average for Inmune Bio (INMB) over the last 7 years, with Q3 2025 value amounting to $35.5 million.

  • Inmune Bio's Assets Average fell 3249.2% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.5 million, marking a year-over-year decrease of 3249.2%. This contributed to the annual value of $48.3 million for FY2024, which is 3042.81% down from last year.
  • As of Q3 2025, Inmune Bio's Assets Average stood at $35.5 million, which was down 3249.2% from $37.7 million recorded in Q2 2025.
  • Over the past 5 years, Inmune Bio's Assets Average peaked at $103.8 million during Q4 2021, and registered a low of $35.5 million during Q3 2025.
  • Moreover, its 5-year median value for Assets Average was $63.3 million (2021), whereas its average is $65.8 million.
  • Its Assets Average has fluctuated over the past 5 years, first surged by 15563.59% in 2021, then plummeted by 3334.32% in 2024.
  • Over the past 5 years, Inmune Bio's Assets Average (Quarter) stood at $103.8 million in 2021, then fell by 20.24% to $82.8 million in 2022, then decreased by 27.72% to $59.8 million in 2023, then dropped by 22.85% to $46.2 million in 2024, then fell by 23.07% to $35.5 million in 2025.
  • Its Assets Average stands at $35.5 million for Q3 2025, versus $37.7 million for Q2 2025 and $38.7 million for Q1 2025.